RSS   Newsletter   Contact   Advertise with us
Post Online Media

Symbiomix Therapeutics appoints David L. Stern as CEO

Symbiomix TherapeuticsSymbiomix Therapeutics, a biopharmaceutical company, announced it has hired David L. Stern as chief executive officer of the company.

Mr. Stern brings to Symbiomix more than 20 years of leadership in strategic planning, business development, reimbursement strategy, and marketing and sales.

Mr. Stern is an independent board member of California Cryobank, a provider of reproductive and stem cell services in the US.

Previously, he was Chief Commercial Officer of Celmatix, a personalized medicine company focused on fertility and women’s health.

Before joining Celmatix, Mr. Stern was Executive Vice President of Global Commercial Operations for OvaScience, where he was responsible for the global launch of the company’s first new fertility treatment, Augment.

He also served as Senior Vice President and Head of Global Business as well as other leadership positions for fertility at Merck Serono, and was director of reproductive marketing at Organon USA, responsible for the company’s contraceptive and fertility portfolio.

Mr. Stern has an MBA from the F.W. Olin School of Business at Babson College, and a Bachelor’s degree in biology from Brandeis University.

He is a member of the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine.


 LATEST MOVES FROM New Jersey 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy